Mpox cases in Congo may be stabilizing. Experts say more vaccines are needed to stamp out virus
November 3, 2024
Congo's mpox cases appear to be stabilizing, with weekly lab-confirmed cases dropping from nearly 400 in July to 200-300 currently, including decline in Kamituga where the new variant emerged. However, WHO notes only 40-50% of suspected cases are tested, and the virus continues spreading in some regions and Uganda. Vaccination efforts face significant challenges, with only 265,000 doses received and approximately 50,000 people vaccinated in a population of 110 million. Health experts remain uncertain about transmission patterns and face difficulties in vaccine distribution across the vast country.
Recent reports suggest a possible stabilization in Congo's mpox outbreak, though significant challenges remain in controlling the spread and implementing effective vaccination programs.
Encouraging Signs:
1. Case Numbers:
- Reduction to 200-300 lab-confirmed cases weekly
- Down from nearly 400 cases per week in July
- Decline observed in Kamituga, the outbreak's origin
- Possible indication of epidemic slowdown
2. WHO Assessment:
- Potential decline in main epidemic
- August emergency declaration may be showing effect
- Some regional improvements noted
- Monitoring ongoing situation
Persistent Challenges:
1. Testing Limitations:
- Only 40-50% of suspected cases tested
- Continued spread in some regions
- Virus reaching new areas, including Uganda
- Uncertainty about transmission patterns
2. Vaccination Issues:
- Limited supply: 265,000 doses received
- Only 50,000 people vaccinated
- Population of 110 million
- Distribution difficulties across vast territory
3. Ongoing Concerns:
- Unclear transmission mechanisms
- Geographic challenges in vaccine delivery
- Need for increased testing capacity
- Regional spread concerns
The situation demonstrates both progress and persistent obstacles in controlling the outbreak, highlighting the need for continued international support and improved resource allocation.